Meet Dr. Steve Rose
Steve is highly respected for his expertise and tireless commitment to finding treatments and cures for vision-robbing retinal diseases.
Posts Tagged ‘amd’
Two days ago, as part of FFB’s “Light the Way to a Cure” fundraising campaign, I shared the story of Corey Haas, as an example of clinical trial participants benefitting from gene therapy studies the Foundation supports. In his case, the therapy’s for a retinal disease called Leber congenital amaurosis. Today, I’d like to share the story of Dick Coulson (pictured, left), who has age-related macular degeneration (AMD), the leading cause of blindness in people age 55 and older. It’s also the target of two treatments that are currently in clinical, or human, trials, both of which are derived from stem cells.
Read more
With a population of about 17,000, Beaver Dam, Wisconsin, is a typical Midwestern community and, according to its website, “a thriving city and wonderful place to call home.” With attractions such as the beautiful 6,000-acre Beaver Dam Lake and the Midwest Cream Cheese Competition, who am I to argue? But most important, at least in the fight against blindness, Beaver Dam plays a big role in the search for knowledge about age-related macular degeneration (AMD).
Read more
The human body has highly impressive mechanisms to protect itself from harm. For example, a group of molecules known as the complement system work with antibodies to kill invading bacteria by punching holes in them and letting the internal contents leak out.
Read more
Tiny Implantable Telescope Can Restore Some Central Vision in AMD
The ideal way to deal with a disease like age-related macular degeneration (AMD) is to prevent it from causing vision loss in the first place. For example, Dr. Barbel Rohrer is developing a Foundation-funded drug that slows retinal degeneration, and resulting vision loss, by bolstering the energy supply of cells in the retina.
Read more
Today, most people who develop wet age-related macular degeneration (AMD) can retain much of their vision thanks to the advent of three treatment options, all administered through repeated ocular injections.